Svelte Medical Systems, Inc. Announces Final Patient Treated in the DIRECT Drug-Eluting Stent Study  
5/15/2012 10:43:29 AM

NEW PROVIDENCE, N.J.--(BUSINESS WIRE)--Svelte® Medical Systems today announced completion of enrollment in the DIRECT (Direct Implantation of Rapamycin-eluting stent with bio-Eroding Carrier Technology) study conducted at four investigational sites in New Zealand. DIRECT is a First-In-Man, multi-center clinical study designed to assess the feasibility of Svelte’s novel ‘All-In-One’ system which combines a thin-strut cobalt chromium stent with a fully bio-absorbable drug carrier and the well-studied sirolimus (rapamycin) drug mounted on a fixed-wire Integrated Delivery System (IDS). The system is low profile and highly flexible, navigating through the vasculature similar to a traditional guidewire, allowing physicians to ‘direct-stent’ coronary artery lesions and eliminate several steps from conventional stenting procedures, thereby reducing procedure time and cost.